Prediction of amikacin dose requirements in neutropenic patients with haematological disease.
This study reports on the use of an easily applied Bayesian forecasting programme (OPT; Clydesoft) to predict amikacin dose requirements in 10 patients with haematological disease and neutropenic fever. OPT-determined dose adjustment achieved therapeutic drug levels for 80% of the peak and 94% of the trough measurements.